首都医科大学学报 ›› 2013, Vol. 34 ›› Issue (4): 496-500.doi: 10.3969/j.issn.1006-7795.2013.04.004

• 更年期及妇科内分泌 • 上一篇    下一篇

孕激素受体膜组分1(PGRMC1)在乳腺癌发生风险方面的研究进展

张颖1, 阮祥燕1, 田玄玄1, 张俊丽1, Alfred O. Mueck2   

  1. 1. 首都医科大学附属北京妇产医院内分泌科, 北京 100026;
    2. 德国图宾根大学妇产医院内分泌与绝经研究中心, 图宾根 D-72076
  • 收稿日期:2013-06-10 出版日期:2013-08-21 发布日期:2013-07-20
  • 通讯作者: 阮祥燕 E-mail:ruanxiangyang@163.com
  • 基金资助:

    国家自然科学基金项目(81172518);北京市卫生系统高层次卫生技术人才培养计划项目(2009-3-52);首都医科大学附属北京妇产医院院内课题PGRMC1。

Development of progesterone receptor membrane component 1(PGRMC1) on the risk of breast cancer

ZHANG Ying1, RUAN Xiangyan1, TIAN Xuanxuan1, ZHANG Junli1, Alfred O. Mueck2   

  1. 1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
    2. University Women's Hospital of Tuebingen, Tubingen D-72076, Germany
  • Received:2013-06-10 Online:2013-08-21 Published:2013-07-20
  • Supported by:

    This study was supported by National Natural Science Foundation of China(81172518); Senior Talents Development Program of Beijing Health System(2009-3-52); The Study of PGRMC1 and it's Assessment Effect of Woman's Breast Cancer Risk, Beijing Obstetrics and Gynecology Hospital, Capital Medical University.

摘要:

乳腺癌是导致女性死亡的主要病因之一,因此现在对于相关标志物及治疗靶位点的研究非常重要。妇女健康启动项目(Women's Health Initiative,WHI)研究10年随访结果,单一雌激素治疗组妇女的乳腺癌风险没有增加,反而有降低,雌孕激素联合治疗组乳腺癌风险增高。此结果表明,在激素替代治疗(hormone replacement therapy,HRT)中孕激素对乳腺癌风险具有负面影响,许多体外研究发现某些合成孕激素对孕激素受体膜组分1(progesterone receptor membrane components,PGRMC1)表达阳性的人乳腺癌细胞有明显促增生作用。那么,WHI雌孕激素连续联合治疗组乳腺癌风险的增加是否可以用PGRMC1来解释?是否PGRMC1可以作为HRT乳腺癌易感者的潜在标志物?现就此方面的研究进行综述。

关键词: 孕激素受体膜组分1, 乳腺癌, 孕激素, 雌激素

Abstract:

Breast cancer is one of the leading causes of death in women, and there is an urgent need for new biomarkers and therapeutic targets. In WHI study, estrogen therapy alone didn't increase the risk of breast cancer, but even reduced it. Continuous combined hormone therapy increased the breast cancer risk. The results showed that progestin has negative impact on the risk of breast cancer. Many experimental studies have showed that some synthetic progesterone can stimuliate the proliferation of MCF7/PGRMC1 breast cancer cells, So whether the increased breast cancer risk in WHI continuous combined arm could be explained by PGRMC1? whether PGRMC1 be developed as a potential marker for breast cancer susceptibility during HRT? We will review the results of related researches.

Key words: progesterone receptor membrane components, breast cancer, progesterone, estrogen

中图分类号: